Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EBITDA (2023 - 2025)

Historic EBITDA for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to -$37.8 million.

  • Upstream Bio's EBITDA fell 10025.41% to -$37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.5 million, marking a year-over-year decrease of 11362.2%. This contributed to the annual value of -$77.8 million for FY2024, which is 9385.75% down from last year.
  • Latest data reveals that Upstream Bio reported EBITDA of -$37.8 million as of Q3 2025, which was down 10025.41% from -$44.3 million recorded in Q2 2025.
  • Upstream Bio's 5-year EBITDA high stood at -$9.4 million for Q3 2023, and its period low was -$44.3 million during Q2 2025.
  • Moreover, its 3-year median value for EBITDA was -$18.9 million (2024), whereas its average is -$24.0 million.
  • Per our database at Business Quant, Upstream Bio's EBITDA tumbled by 8365.67% in 2024 and then tumbled by 15283.35% in 2025.
  • Over the past 3 years, Upstream Bio's EBITDA (Quarter) stood at -$14.3 million in 2023, then tumbled by 83.66% to -$26.3 million in 2024, then plummeted by 43.76% to -$37.8 million in 2025.
  • Its last three reported values are -$37.8 million in Q3 2025, -$44.3 million for Q2 2025, and -$32.0 million during Q1 2025.